Do you hate injections? Researchers from China are developing a vaccine against the emerging coronavirus “Covid-19” in the form of a spray, what advantages does it provide? Are there other researchers working on the same method?
Chinese researchers have developed a vaccine for the emerging coronavirus “Covid-19” in the form of a spray, and submitted a request to allow its emergency use to the health authorities in China. Read also Symptoms of the Corona virus .. 33 signs of infection Symptoms of black fungus.. 18 signs of infection Learn about the symptoms of the Indian strain of the Corona virus Side effects of eight types of corona vaccines in one table
The vaccine was developed researchers by led by Chen Wei jointly with the company Chinese biotechnology CanSino Biologics Inc.
Can sino Biologics had developed a single-dose vaccine for the Corona virus, based on viral vector technology, and given by injection.
Qin said Wei said vaccine requires only fifth amount vaccine Corona virus required given by injection does not need to stored and transferred to cold chain, in speech at forum Boggiong innovation in Shanghai on Thursday, as quoted “euronews ” (Euronews).
Chen expected this new vaccine to improve accessibility and reduce the cost of the Corona vaccine.
According to statements by experts, they are optimistic about this new type of vaccine, which they believe is better than injectable vaccines in terms of efficiency and comfort.
The current injectable COVID-19 vaccine is 0.5 milliliters per dose, said Tao Lina, a vaccine expert in Shanghai. He told the Global Times that if Chen’s nasal spray vaccine could achieve the same protective effect with a dose of just 0.1 milliliters, “it means it has a higher immunogenicity.”
The higher efficiency may come from the way the vaccine enters the body, Tao said, explaining that it is inhaled directly through the nose, mimicking the natural infection of the COVID-19 respiratory virus.
With only a fifth dose of the injectable COVID-19 vaccine, producers can produce five times more nasal spray vaccines with the same production capacity as injectable vaccines, which can contribute to accelerating vaccination in China, Tao added.
Chen said the vaccine has been requested for emergency use by the National Medical Products Administration of China.
The next generation of COVID-19 vaccines
At the beginning of last May, Peter Loftus and Gregory Zuckerman wrote in the Wall Street Journal that the next generation of Covid-19 vaccines may be tablets or sprays.
They added that drug manufacturers and government laboratories are developing doses that are easier to carry and transport to treat coronavirus variants and avoid future epidemics.
These new vaccines – from US government laboratories and companies; Including Sanofi SA and Altimmune Inc. And Greatstone Oncology Inc. also has the potential to provide long-lasting immune responses that are more effective against newer and multiple viral variants, which may help avert future epidemics, the companies say.
For example, vaccines currently licensed for use in the United States from Pfizer and Moderna must be transported and stored at low temperatures and require two doses.
New vaccines could “form some improvements” over those restrictions and accommodate vaccination efforts more easily in rural areas, said Gregory Poland, a professor and vaccine researcher at the Mayo Clinic in Rochester, Minnesota.
Removing the virus from the respiratory tract
There are 277 vaccines for corona under development globally, according to the Wall Street Journal, of which 93 have entered human tests, according to the World Health Organization. Most vaccines are injectable, but there are 2 oral formulations and 7 nasal spray formulations.
Altimon says that a nasally sprayed COVID-19 vaccine may stimulate a type of immune response that can help clear the virus from the respiratory tract.
Many next-generation vaccines are in early-to-mid-stage human testing, which means they may not become available until later in 2021 or 2022. There is no guarantee that vaccines will succeed in testing, and some of the companies developing them – such as Ultimon and Greatstone Technology – are not yet available. It has never brought a vaccine to market.
There is a challenge that companies developing next-generation COVID-19 vaccines may face. There may be enough people willing to receive unproven vaccines or a placebo in clinical trials when they can also get one of the approved vaccines that have already been shown to be effective.
A spokeswoman for Ultimon said volunteers were getting more difficult to find, but the nasal spray formulation had enough oomph to continue to attract volunteers.
and if it proves to protect people safely from COVID-19; New intranasal vaccines could be easier to administer and could help provide booster doses to people who have already received the vaccine.
“It is very important in the future to have vaccines that are easier to handle and have better cold chain properties,” said John Mascola, director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases in the United States.
Altimon is developing a COVID-19 vaccine to be given as a nasal spray, and Scott Roberts, Altimon’s chief scientific officer, said, “It’s an easy and very effective way to give the vaccine.” “You don’t need needles and syringes.”
The vaccine uses a modified version of a harmless virus called “adenoviruses”, which is designed to carry a genetic code that directs the body’s cells to make the spike protein from the coronavirus. This induces an immune response, including the production of antibodies in the blood, building a defense against the real virus.
Because the Ultimon vaccine is given as a nasal spray; It may also trigger a type of immune response known as mucosal immunity, which can help clear the virus from the respiratory tract, thus helping reduce transmission of the virus by vaccinated people, according to Dr. It can prevent infection on its way and also neutralize it when it is on its way out; that can be very important from a public health perspective.”